Publications by authors named "M Karuturi"
Purpose: To evaluate patient-reported health-related quality-of-life (QoL) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced/metastatic breast cancer (ABC) treated with palbociclib in the longitudinal real-world study, POLARIS.
Methods: Data were prospectively collected from adult patients with HR+/HER2- ABC treated with palbociclib plus endocrine therapy (ET) in routine clinical practice. QoL was assessed with the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 (EORTC QLQ-C30) and reported at baseline and months 6, 12, and 18.
Article Synopsis
- Strict eligibility criteria in RCTs limit data applicability to diverse real-world populations; thus, the POLARIS study focuses on hormone receptor-positive/HER2-negative advanced breast cancer patients receiving palbociclib and endocrine therapy.
- The study analyzed demographic and treatment data from 1,250 patients over a span of nearly three years, reporting response rates of 34.0% in first-line treatment and 21.8% in later lines, with median progression-free survival and overall survival varying by treatment line.
- Results indicate that outcomes in this diverse population align with previous clinical trial data, reinforcing the efficacy of palbociclib combined with endocrine therapy for patients with HR+/HER2- advanced breast cancer.
Article Synopsis
- The study aimed to assess how palbociclib treatment affects health-related quality of life (HRQoL) in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer through a systematic review of literature up to June 2023.
- A total of 15 studies, including randomized controlled trials and real-world evidence studies, indicated that HRQoL is generally maintained or even improved in patients treated with palbociclib compared to monotherapy.
- The findings showed consistent positive effects on individual patient outcomes like pain and fatigue, with comparable results across diverse patient groups, suggesting that HRQoL is largely preserved when palbociclib is added to endocrine therapy.
Background: HER2-positive breast cancer is traditionally treated with neoadjuvant systemic therapy (NST), but optimal treatment sequencing is less clear in patients with small tumors. We investigated clinicopathologic and oncologic outcomes in early stage HER2-positive breast cancer.
Patients And Methods: An institutional database was queried to identify patients with cT1-2 (≤ 3 cm) N0M0, HER2-positive breast cancer treated from 2015 to 2020 and compared upfront surgery and NST cohorts.